Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Chris Parkinson
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q2 (8 quarters).
- Questions
- 94on tracked calls
- Challenge rate
- 2%2 of 94 questions
- Companies
- 14questioned at least once
- Reporting periods
- 8with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 94 of 94 questions from 14 companies
APDAir Products11 questions · 7 reporting periods · 2 of 11 challenging
Calendar 2026 Q2
how long those projects were being assessed, in terms of you becoming CEO?
Show response
Eduardo said one large Taiwan project dates to 2022, but the recent backlog wins came in the last 12 months, crediting a semiconductor super cycle; roughly two-thirds of the opportunity pipeline is electronics.
in your 10-K, the debt was listed, I believe, and forgive me if I missed something, but around $4.7 billion
Show response
Melissa clarified there is no discrepancy: the ~$5.2B is the carrying value of NGHC net debt, and deconsolidation to roughly $11-11.5B net debt occurs after the plant is commissioned and on stream.
Calendar 2026 Q1
just the way your second half guidance kind of just works out, it implies a fairly low single-digit growth rate in terms of EPS for the fourth quarter
Show response
Melissa cited uncertainty in Asia and Europe macro environment, turnarounds moved from Q2 to Q3/Q4, and monitoring Strait of Hormuz supply chains as reasons for conservative H2 outlook.
in the Samsung release from yesterday, you used the phrase, the greatest investment -- the largest investment in the semiconductor industry
Show response
Eduardo confirmed Samsung is larger than prior $900M TSMC project. Fifth phase of the site with volumes approximately 3x larger than Phase 1. Declined to disclose exact amount.
Calendar 2025 Q4
How do you see these things progressing throughout the year?
Show response
Eduardo expects price and productivity contributions for remaining quarters to be similar to Q1 levels. Helium remains the exception in an otherwise strong pricing environment.
how the investment community should be thinking about content when we're looking at things like N2, HBM, et cetera, et cetera
Show response
Eduardo highlighted accelerating investment decisions by chip manufacturers over last 24 months. Combined current CapEx near $1B with similar pipeline expected to be decided in next 12 months. Melissa confirmed new asset contributions weighted to back half of FY2026.
Calendar 2025 Q3
can you talk about just kind of how we should be thinking about the run rates from Uzbekistan as well as like GCA
Show response
Eduardo confirmed Uzbekistan running at very high rates after scheduled maintenance. GCA still being brought to completion but expected to contribute in FY2026.
can you just go over kind of how we should be thinking about the intermediate to long-term growth algorithm that you have in your portfolio and how that exposure evolves
Show response
Eduardo highlighted electronics at 17% of sales with very strong position. New projects being commissioned, with additional investments in Asia and expected new project announcements in 2026.
Calendar 2025 Q1
is this commentary about those specific projects and how they were managed? Or is it more of a larger indictment on your view of blue hydrogen
Show response
Eduardo clarified underperformance is project execution and cost overrun issues, not fundamental blue hydrogen strategy concerns. Customer contracts performing as expected.
Calendar 2024 Q4
how should the Street be thinking about obviously some of the past headwinds in the helium business and electronics recovery and just general macroeconomic conditions in China?
Show response
Melissa acknowledged China remains challenging with no material improvement expected, noting focus on productivity and things within management's control.
Calendar 2024 Q3
can you perhaps just give us a little bit more detail on the various stages on how we should be thinking about that development
Show response
Seifi provided extensive detail on CO2 sequestration validation ($75M spent on seismic studies), Class 6 well application, and financing strategy with 2028 expected on-stream.
CFCF Industries11 questions · 6 reporting periods · 0 of 11 challenging
Calendar 2026 Q2
I am curious on your interpretation of The U. S. And coastal benchmarks typically trading at a discount.
Show response
Frost acknowledged NOLA trades at a discount and said CF built a larger-than-normal urea export book, expecting the market to tighten as deferred demand returns.
Calendar 2026 Q1
how are you thinking about Blue Point number two? Is there anything else the industry should be doing to work with U.S. policymakers?
Show response
Chris confirmed market was already tight before 2026 and now even more capacity needed with higher costs and risk globally making Blue Point look better. Wants to understand Blue Point number one before committing to number two. Cash generation expected to be significant over next several years with opportunities within network and elsewhere for high-return margin enhancement or production increases.
are you thinking about things differently this year?
Show response
Bert said approach to fill varies annually in timing, communication, and execution. Last year's early and open communication with customers on launch date, volume, and price was very successful and will likely be replicated thematically. Internally evaluating highest-value use of nitrogen molecule across product lines and export opportunities. Expects fill to be a Q3 event.
Calendar 2025 Q4
How are you thinking about order book flexibility into this year? I mean farmers are just now getting some deferred direct payments
Show response
Bert said CF carried inventory into 2026 deliberately given supply-demand dynamics. Just finished TFI meetings in Orlando with customers. Early applications starting in Texas, Kansas, Oklahoma, Nebraska with potential for early spring similar to 2012. Lower inventories in upper Midwest, Canadian plant issues from winter storms, and 93-95M corn acres all contributing to logistics-driven execution focus.
do you think the buy side and the Street is missing something more pronounced in Japan that's still ongoing?
Show response
Chris agreed the market may be underappreciating Japan. Multiple competitor low-carbon ammonia projects cancelled or deferred. JERA and Mitsui secured contract-for-difference awards with 60% of Blue Point output going to new demand sources that did not exist a year ago. Positioned as both low-carbon opportunity and new incremental demand beyond 1-2% legacy agricultural growth.
Calendar 2025 Q3
how much of the demand and the price strength do you attribute to the supply side of it versus the fact that demand, I think, broadly speaking, throughout the year-to-date has also been pretty healthy
Show response
Tony said demand outlook is easier to forecast and looks very strong for 2026 planting. Supply disruptions harder to predict, but many affected regions are on the high end of the cost curve. Bert noted 5 million tons lost from global conflicts plus late Chinese export entry pushed market higher.
What have you, Bert and Chris learned the most from all of those efforts over the last 12 or so years that Chris and his team can essentially apply the Blue Point
Show response
Tony cited full FEED study before FID versus 2012 announcement timing, modular construction replacing stick build, and leveraging experienced personnel from prior expansions. Chris emphasized early operator hiring for training years before startup, which enabled prior plants to exceed nameplate within months.
Calendar 2025 Q2
how should investors be thinking about the sustainability of these dynamics into 2026. And have you seen actually anything improved?
Show response
Bert detailed multiple tightening factors: tariff disruptions to Q2 imports, Southern Hemisphere peak season with India closing 2M ton tender at elevated prices, Brazil needing 1M tons monthly, Northern Hemisphere 2026 purchasing starting, and Egypt/Iran/Trinidad chronic gas shortages.
how should investors be thinking about the uses of cash? Because on the one hand, obviously, a lot of people are going to be looking for buybacks
Show response
Tony said Blue Point spend starts slower then accelerates in years 3-4 for module deliveries and construction. If cash generation exceeds expectations, excess capital will be deployed more expeditiously against the $2.4 billion share repurchase authorization.
Calendar 2025 Q1
there's been a lot of debate around the intermediate to long-term cost curve, just given gas supply issues elsewhere in the world, geopolitics, so on and so forth
Show response
Tony argued US gas cost advantage is sticky and not compressing despite new LNG capacity, citing data center power demand growth offsetting liquefaction additions. Described US as best place in the world to build nitrogen assets.
Can you kind of walk us through how we should be thinking about not only those baselines and what's locked in versus the variability of the tons?
Show response
Tony outlined roughly 650,000 tons at 40% ownership with half earmarked for UK low-carbon ammonium nitrate production leveraging CBAM. Partners offtake going to Asia. Emphasized relatively small tonnage versus overall CF operation.
DDDuPont11 questions · 6 reporting periods · 0 of 11 challenging
Calendar 2026 Q1
in terms of your balance between [ PB, ] biopharma, med device, and some of the larger secular trends that's going on
Show response
Koch sized healthcare at ~$2B total (~$1.2B Tyvek, remainder Spectrum/CDMO). Robust M&A pipeline of accretive, affordable assets. Aramids closed April 1 ($1.2B gross, $1.1B net). $275M ASR announced. Below 2x leverage target with dry powder for deals.
a broader question on pricing in terms of the second quarter and also the second half environment
Show response
Franzen quantified ~$90M incremental costs fully offset by surcharges and price increases. Majority started May 1 due to customer notification requirements. Q2 will see ~$25M price on top line. Full run rate in H2.
Calendar 2025 Q4
what are you the most enthusiastic about as you go through '26 and perhaps even the longer-term growth algo
Show response
Koch highlighted all three healthcare sub-segments contributing mid-to-high single-digit growth, with outsized exposure to cardiovascular procedures which grow faster than general surgery average.
do you feel as though you're missing any scale? Do you feel as though there's an easier portfolio
Show response
Koch confirmed leading positions in RO, ion exchange, UF, and nanofiltration. Further filtration M&A difficult regulatory-wise given market leadership. Looking beyond filtration into adjacent water spaces. Recently added RO membrane capacity in China.
Calendar 2025 Q3
What do you think the Street is missing the most about the independent company's outlook
Show response
Koch identified two issues: short-term consensus confusion from Aramids disc-ops noise, and longer-term misperception as a chemical company vs multi-industrial with matching financial performance.
Do you have the willingness or desire to get further into metering or anything else kind of as a tangential kind of growth theme
Show response
Koch ruled out metering on valuation grounds. Instead looking at systems plays and filtration beyond water (food & beverage, microelectronics, dairy) leveraging ion exchange resin capabilities.
Calendar 2025 Q2
could you just quickly comment on what you're seeing across semi advanced packaging and ICS in terms of data center, HPC and hyperscalers
Show response
Kemp highlighted N2 and HBM content gains, broader market recovery potential, with more detail coming at September Investor Day.
Calendar 2025 Q1
can you just talk about your competitive positioning? Like, what are we going to be talking about as we approach November 1
Show response
Kemp highlighted CMP expansion from front-end to back-end packaging, metalization share gains, and 2.5D/3D packaging scale-up with foundry customers.
what you're seeing across both semi-tech and ICS? And how you're thinking about the China market, versus just the non-China market
Show response
Kemp outlined flat China Semi for full year (normalizing from elevated levels), high-single-digit rest-of-world for both Semi and ICS.
Calendar 2024 Q4
could you just give us a little bit more perspective on how you see things shaping up across Safety, Shelter and Water throughout '25
Show response
Koch broke down IndustrialsCo into 40% healthcare/Water (mid-to-high single digit growth) and remaining portfolio (low single digit), giving clear segment-level guidance.
could you sit on kind of the key drivers of the remainder of the portfolio? And just any differences based on geography as well?
Show response
Koch mentioned thermal management (Laird acquisition) as a key growth driver alongside AI packaging, but geographic detail was limited due to audio quality issues.
BALLBall Corporation8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2025 Q3
what quarter in 2026 do you think that's roughly going to normalize in terms of improving the Street's ability to better project volume versus operating leverage
Show response
Fisher explained 2026 will still be constrained at ~99% asset utilization, making leverage flow-through unpredictable. Cleaner leverage in 2027 with Oregon capacity online. Contrasted with Europe where excess capacity enables more traditional leverage.
what's your kind of latest and greatest assessment based on what you're hearing from your customers in terms of the outlook for '27, '28
Show response
Fisher described Europe as a land of opportunity driven by glass-to-can substrate shift. Investment must be methodical due to European labor laws, Works Council requirements, and environmental permitting complexity. Encouraged by returns on deployed capital.
Calendar 2025 Q2
do you see yourself kind of trending towards the higher end of those ranges
Show response
Fisher confirmed high end of range this year. Portfolio repositioning from beer to nonalcoholic showing benefits. Won't move off 2-3% long-term range yet but well above it currently.
what have been the two best surprises? What have been the two worst just given all the puts and takes that we've seen
Show response
Fisher: Europe largely in line, South America mixed (Brazil under, others over), NA energy far better than expected while beer underperforms. Net positive. Cans winning substrate shift.
Calendar 2025 Q1
Can you just hit a little bit more on the trends that you're seeing in Latin America
Show response
Fisher expects above long-term 4-6% growth in South America for 2025 from portfolio recovery. Brazil at 2-3% industry growth but Ball grows faster from Chile/Paraguay/Argentina recovery.
how should we be thinking about just the supply demand dynamics across the region
Show response
Fisher framed European can penetration at high-20% vs global 40-50%. Decadal substrate shift underway. Must be methodical about capacity additions due to European labor laws and permitting.
Calendar 2024 Q4
how much confidence do you have in that growth rate, at least in Brazil and forecasting that aluminum should still be the primary substrate
Show response
Fisher expects 2-4% Brazil growth but Ball's portfolio including Chile/Paraguay/Argentina recovery drives 4-6%+ growth on favorable comps.
Can you just us a little bit more color since you went over the beer thesis on what you're seeing in energy markets, in particular, in both the U.S. and Europe
Show response
Fisher differentiated Europe (sustained high mid-single-digit energy growth) from NA (more aggressive pricing driving expected return to growth in 2025).
QQnity Electronics, Inc.8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
when you look out 2 to 3 years, do you see Qnity’s portfolio primarily based
Show response
Kemp said the mix is still roughly 80-20 logic-to-memory (HBM/DRAM a touch faster), with data center ticking up and consumer electronics slower.
when do you think we’ll see the, you know, the vast majority of these benefits? What are you most excited about?
Show response
Kemp framed the announcements as long-running innovation now more visible as a pure-play, citing POR wins across every line of business, without dating benefits.
Calendar 2026 Q1
Could you speak to your assumptions in terms of what appears to be an accelerating mainstream recovery
Show response
Kemp provided detailed utilization data (mid-70s to high 70s/low 80s) and highlighted AI demand extending into mainstream. Also covered POR wins across both segments.
Can you just speak to further the kind of the broader opportunity, how you see kind of the run rate growth
Show response
Kemp confirmed Advanced Packaging, Thermal Management and AI PCBs as fastest-growing areas, expected to remain so. Shorter cycle wins scaling quickly.
Calendar 2025 Q4
How should we be thinking about op leverage throughout the year in both semi and ICS
Show response
CEO detailed ICS margin expansion of 175 bps driven by favorable mix. Semi margins in mid-30s with incremental R&D investment for advanced node scaling. Expects similar dynamics in 2026 with ICS margins growing faster.
in terms of just the free cash flow in terms of the outlook conversion, where you currently are and where you expect to be
Show response
CFO explained FCF step-down from $706M to ~$500M driven by elevated CapEx at 9% of sales for local-for-local investments, IT independence and transformation. CEO framed long-term FCF at mid-teens percent of sales.
Calendar 2025 Q3
is there anything you could point to that feels different in terms of the sustainability of the said recovery
Show response
CEO pointed to two key differences: cleared inventory positions and first signs of mature logic utilization trending positively. Macro factors in broader economy still a variable.
What are the 1 or 2 most consistent areas of feedback that you're receiving
Show response
CEO cited two key themes: (1) deliver steady, consistent results and beat guidance, (2) investors are positively surprised by the natural fit and technology convergence between the two segments.
CTVACorteva7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
kind of curious on what you are the most excited about in terms of the market
Show response
Incoming New Corteva CEO Luke Kism emphasized portfolio diversification, differentiated technology and the crop protection pipeline with 7 new actives.
Calendar 2026 Q1
Where do you think investors should be focusing the vast majority of their time into the second half?
Show response
Chuck gave expansive answer covering both Vylor and new Corteva, citing 7 new active ingredients, biologicals, hybrid wheat, gene editing, and $1B licensing revenue over the next decade.
Calendar 2025 Q4
could you just kind of help us break down Slide 27 a little bit more with the Bayer litigation
Show response
Chuck said agreement provides freedom to operate and accelerates corn licensing to 2027 (years ahead of plan), opens cotton licensing market, and resolves all outstanding litigation with Bayer. Judd detailed triple-stack options 5 years earlier, third-gen above-ground 2 years forward, and reciprocal cotton licensing.
Calendar 2025 Q3
what do you think is the most missed of what you've laid out?
Show response
Chuck said CP formula hasn't changed, differentiated tech focus. Separation opens more doors for Seed Applied Technology ($0.5B business) and new retailer/co-op partnerships. Committed to 6-7% R&D.
Calendar 2025 Q2
Could you just discuss kind of the pricing strategy into the end of the season?
Show response
Judd said 2026 seed pricing looks low single digits driven by mix (Vorceed/PowerCore), germplasm performance, and organic lift. Chuck noted H1 seed EBITDA up $250M with 280bp margin gain.
Calendar 2025 Q1
can you just briefly speak about, just across the Americas, where you feel the most enthusiastic about what's left to come?
Show response
Chuck highlighted out-licensing strategy, hybrid wheat ($1B revenue potential, 2027 launch), and canola biofuels. Judd detailed 95M corn acres, E3 performance, and Latin America expansion.
Calendar 2024 Q4
how should we think about these potential positives as they're evolving into the season
Show response
Chuck provided comprehensive market overview with bullish fundamentals. David walked through upsides and downsides, confirming 10% EBITDA growth target is balanced.
Show 8 more companies
ECLEcolab7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
kind of how you see the trajectory of some of the biopharma applications. Versus some of the purification and resins
Show response
Beck said life sciences is running ahead of its 10% to 12% long-term target, with a new plant in China relieving the capacity constraints that had capped purification.
Calendar 2026 Q1
I'd love it if you could kind of walk us through the intermediate to longer-term puts and takes of those targets
Show response
Kirkland noted 500bps OI expansion over last few years with 100bps expected this year and 100bps more to reach 20%. Beck said 20% is a given and focus is on what comes after.
Calendar 2025 Q4
can you just kind of give us some insights on how you're thinking about that business in 2026
Show response
Beck described Water ex Basic Industries/Paper at 5% growth in Q4. F&B United driving acceleration with Hygiene and Water merged in North America, expanding globally. GHT close to $1B growing strong double-digit. Paper margin at 13% but still acceptable. Second-highest Water margin quarter in five years.
Calendar 2025 Q3
Could we just dig in a little bit more into the Life Sciences segment?
Show response
Beck described accelerating Life Sciences trajectory. Q4 growth will moderate vs 70% bioprocessing comp but underlying double-digit bioprocessing growth continues. China capacity opening mid-2026 will unlock water purification growth. Margins mid-teens reported, mid-20s underlying, clear path to 30%.
Calendar 2025 Q2
what do 2Q results tell you about your longer-term opportunities by segment?
Show response
Beck highlighted I&S at record margins driven by labor automation for customers, digital technology adoption, and share gains. 1-2pp growth drag from strategic exits masking underlying momentum. Combination of value pricing, productivity, and digital driving sustained expansion.
Calendar 2025 Q1
In the intermediate term, what are you the most enthusiastic about?
Show response
Beck picked data center cooling as top growth engine, citing unique cooling expertise, fluid monitoring, 3D TRASAR integration, and chip replacement cycles shortening.
Calendar 2024 Q4
is there just a general mathematical equation that would get us to, let's say, more of a mid-single-digit, like a 5 or a 6% growth rate
Show response
Beck explained Global High Tech at $300M+ will increasingly influence industrial growth profile as data center and fab businesses scale relative to total.
MOSMosaic Company (The)7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
does that basically imply both New Wales and Riverview are somewhere in the low to mid-70s
Show response
Bodine confirmed mid-70s rates at New Wales and Riverview, 40% at Bartow, Louisiana 100% down, all constrained by contract sulfur. The network is optimized week to week around sulfur availability and active DAP demand, not running any site hard.
Calendar 2026 Q1
can you just talk about how you're thinking about the 2, and probably perhaps more so the 3Q order book
Show response
Bodine confirmed international phosphate prices at premium to NOLA with demand more active in Asia than Americas. Pivoting exports to international markets where possible. At anticipated Q3 sulfur prices, even international stripping margins may not justify full production. Preserving Q2 sulfur inventory for longer as hedge against deterioration. Wang highlighted India and Pakistan demand supported by government subsidies.
Calendar 2025 Q4
can you just kind of give us a walk-through of the phosphate production or asset portfolio, where we were, where we kind of were trending
Show response
Bodine provided facility detail: Bartow at 80%+ with no remaining turnarounds. Louisiana at 80%. Riverview approaching 80%. New Wales in turnaround, expected at 80% by Q2 exit. Need low-80s operating factor across all facilities for 8M ton run rate. Q4 produced 1.7M tons despite Bartow turnaround and deliberate production adjustment. Luciano: each 100K ton quarterly increase yields $7-8/ton cost absorption improvement, path from $112 to sub-$100 achievable at 2M ton quarterly rate.
Calendar 2025 Q3
Can we just get an update on after the issues in late September, how you performed in October versus expectations
Show response
Bodine acknowledged September press release issues are behind them but normalization is slower than expected. Attributed to lost institutional knowledge from 5 years of not running at full rates, workforce turnover created gaps in operational practices like startup procedures and product switches. Invested additional $100M CapEx + $100M maintenance expense above normal. Brought on external consultants. Shifted guidance philosophy to trailing proven rates rather than forward promises.
Calendar 2025 Q2
What was your run rate roughly in July? And how are we -- where are we trending in August and September
Show response
Bodine stated July run rate was below expectations due to New Wales pump delay extending to month-end. Early August data is encouraging. Louisiana performing better than the asset health graphic suggests. Bartow running at 2M ton annualized capacity. No extraordinary maintenance scheduled going forward. Q3 guidance of 1.8-2.0M tons reflects confidence.
Calendar 2025 Q1
if we stood at in your boardroom during the first quarter, how do you have adequate fully assessed yourself when it came to Bartow, New Wales and kind of getting into Riverview and Louisiana
Show response
Bodine reported unanticipated reactor brickwork at New Wales added extra turnaround days. First gypsum handling train replacement had commissioning issues but is now at target rates. Accelerating remaining two trains into H1 to insulate H2 performance. Both Bartow and New Wales now running at target rates.
Calendar 2024 Q4
Your press release mentioned it's your belief that 700,000 tons were sacrificed in 2024 for processed phosphate
Show response
Bodine explained sulfuric acid turnarounds are back on schedule and identified phosphoric acid bottlenecks at New Wales requiring accelerated H1 CapEx, with second half at max capacity run rate.
PPGPPG Industries7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
Is there anywhere else you think you should be stealing more share?
Show response
Walked business by business through share position and closed by noting no business where he was concerned about losing share.
Calendar 2026 Q1
perhaps you could just give us kind of the puts and takes. Obviously, you've been very proactive in pricing in terms of those dynamics, which is helpful in terms of to contemplate
Show response
Knavish laid out H2 margin drivers: aerospace growth (good margin), refinish recovery (big margin impact from negative leverage reversal), Mexico growth (good margin contributor). All mix tailwinds plus pricing actions underway and industrial share gains launching. Morales added European plant closures in H2 provide cost structure benefit.
Calendar 2025 Q4
Could you just add a little bit of insight on what you saw in the fourth quarter and how you're thinking about everything in 2026 in terms of breaking that growth down
Show response
Knavish broke down by business: aerospace/Mexico/PMC getting macro help; packaging crushing it (double-digit, largely Europe share gain); auto OEM outperforming (share gain); general industrial flat. Growth is a combination of all three factors but macro has not fundamentally changed.
Calendar 2025 Q3
what are the 1 or 2 things you think we should be all focusing on in terms of volume growth, subsegment market outperformance
Show response
Knavish provided early 2026 framework: macro not expected to improve much, refinish carryover challenges through H1 2026 with comp issues, first half particularly difficult. Offsetting with organic growth momentum, self-help, raw material supply chain remaining long. Net: 2026 looks softer in H1 than earlier envisioned.
Calendar 2025 Q2
where would you have the greatest confidence over the next 1.5 years or perhaps even longer in terms of your ability to significantly outgrow markets
Show response
Knavish gave comprehensive business-by-business outlook: aerospace (continued outperformance), refinish (out-of-can innovations), traffic (infrastructure spending), PMC (fire protection, marine aftermarket), packaging (BPA regulations in Europe), Comex (post-pause growth), industrial coatings (share gains). Reiterated long-term algorithm: 2-4% organic growth, 8-10% EPS growth, $1B adjusted FCF.
Calendar 2025 Q1
Can you talk a little bit more about the aerospace opportunity and just go through aftermarket OE and military
Show response
Knavish bullish across all aerospace segments, cited multi-year backlogs. COVID-era inventory depletion still being rebuilt. Active debottlenecking projects across facilities with larger capital investments under engineering analysis. Morales added manufacturing flexibility between OEM/aftermarket/military and noted military growth as new post-pandemic leg.
Calendar 2024 Q4
can you just talk about how you and your teams are now thinking about the respective growth rates of those end markets in terms of share gain, market outperformance
Show response
Knavish provided segment-by-segment growth drivers: Arch tied to housing/GDP plus share gains, Performance tied to stable aftermarket demand, Industrial tied to production plus technology-driven share gains.
SHWThe Sherwin-Williams Company7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
is there anything else in terms of major initiatives that you feel the Sherwin team should be even more aggressive on?
Show response
Petz pointed to contractor data and distribution scale; Meisenzahl added ERP modernization, CRM and digital demand signals as the biggest untapped lever.
Calendar 2026 Q1
Can you just give us kind of a quick update, given the current dynamics, on how you are thinking about gross spend
Show response
Heidi Petz provided detailed segment-level share gain examples across residential repaint, commercial, property maintenance, protective and marine, and refinish. Described company as better positioned than ever.
Calendar 2025 Q4
should we talk about some of the things that are more or less in your control in terms of your guidance
Show response
Jim walked through raw material pressure areas (packaging, non-TiO2 pigments, resins); Ben added healthcare mitigation and interest expense.
Calendar 2025 Q3
Is there a scenario out with for which you see Sherwin consistently being at or above 50% gross margin absent any material volume recovery.
Show response
Al declined to commit to 50% sustained GM without volume growth but noted positioning and Paint Stores higher-margin mix contribution going forward.
Calendar 2025 Q2
Has that changed your calculus at all on how you are thinking about allocating growth spends between, you know, PSG and consumer brands.
Show response
Heidi emphasized aggressive customer acquisition amid competitor disruption; Al noted Consumer Brands must manage expenses but will not cut to hurt long-term growth; PCG's disciplined cost control positions for recovery.
Calendar 2025 Q1
Could we take a step back and just look at PCG just given everything that's going on in the world?
Show response
Heidi walked through each PCG division: refinish half FX-related with new account installs; general industrial under pressure; coil momentum continues; packaging winning back temporary share losses; industrial wood tied to new residential.
Calendar 2024 Q4
what are the two to three largest growth or opportunities that you see in '25 and '26
Show response
Heidi pointed to res repaint outperformance driven by premium product innovation (labor productivity story), plus coil and packaging on the performance side with relentless new-account focus.
DOWDow Inc.4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2025 Q4
How do you see that evolving over, let's say, the first half of '26 through '27, '28, just given where we are in the cycle?
Show response
Fitterling cautioned against extrapolating Q4/Q1 bottom-of-cycle data. Carter noted November set total PE sales record; industry inventories drew 400M lbs through November. Conditions support January price increases.
Calendar 2025 Q3
How, if any way, whatsoever, does that filter in to your return assumptions, your longer-term term resumptions on Alberta?
Show response
Fitterling said Alberta stays first quartile in any curve scenario. Focus on rightsizing Europe to European market. Key question is when demand returns and trade regulation stabilizes for excess Chinese capacity.
Calendar 2025 Q1
one could argue that the current situation could potentially incentivize the Chinese to further let's say, you know, push a little bit harder in domestic capacity
Show response
Fitterling noted landed NGL cost in China not competitive vs naphtha at current oil prices. Specialized grades limit domestic substitution. Domestic demand not driving capacity adds.
Calendar 2024 Q4
just how you're thinking about some of the EU assets by country. And I think last summer you were going over the Netherlands and Germany
Show response
Fitterling gave country-by-country breakdown: Spain decent energy costs, Netherlands relatively competitive but evaluating ethylene/propylene balances, Germany depends on upcoming election.
IFFInternational Flavors & Fragrances4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2026 Q2
Can you just kind of break down how we should be thinking about the differences and kind of the drivers of the recovery in the Consumer Fragrance business?
Show response
Erik praised Scent leadership and the rebuilt R&D pipeline; DeVeau sized H2 Fine Fragrance at mid-single-digit, Consumer Fragrance normalizing to low single-digit, and Fragrance Ingredients under YoY pressure as it shifts to higher-value naturals.
Calendar 2025 Q4
Is it safe to say that you are still investing in that business? And then you already mentioned the half-on-half trends, which I appreciate. But can you just talk about
Show response
Erik emphasized Health weakness was isolated to North America, with Leticia Goncalves's new leadership team executing improvement plan. Pipeline expected to deliver growth again in 2027. Affirmed continued investment commitment given the business's importance and IFF's strong capabilities.
Calendar 2025 Q2
Could you just hit a little bit more on probiotics markets? It seems like there's been some inconsistencies not only in the market, but also geographic and also some of your peer commentary
Show response
Erik acknowledged IFF lost its R&D edge in probiotics but has been reinvesting since early 2024, with pipeline strengthening for 2026 delivery and full strength by 2027. Leticia Goncalves strengthening commercial capabilities. Sees GLP-1 trend as creating additional probiotic opportunities.
Calendar 2025 Q1
could you talk a little bit more about the growth spend you've been seeing in scent and H&B progress you've made as well as your own assessment of your competitive position
Show response
Erik confirmed growth spending is on track with strengthening commercial and R&D pipelines. Not backing down on investment despite macro challenges, offsetting with productivity.
ALBAlbemarle Corporation1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q2
it looks like COGS were about a $150 million headwind. And that includes the spodumene price flow through
Show response
Neal declined an exact split but said the spodumene inventory lag was the largest COGS driver, with higher Q2 ~$2,500/ton spodumene rolling through in the third quarter.
LINLinde plc1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
is it wrong to think about Europe slightly differently these days? Or is it still essentially the status quo over the longer term?
Show response
Sanjiv said directionally improving with Germany EUR 1T and NATO 5% commitments. But procurement and permitting will take time, don't expect early projects before late next year.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| APD Air Products | 11 | 18%2 of 11 questions |
| CF CF Industries | 11 | 0%none of 11 questions |
| DD DuPont | 11 | 0%none of 11 questions |
| BALL Ball Corporation | 8 | 0%none of 8 questions |
| Q Qnity Electronics, Inc. | 8 | 0%none of 8 questions |
| CTVA Corteva | 7 | 0%none of 7 questions |
| ECL Ecolab | 7 | 0%none of 7 questions |
| MOS Mosaic Company (The) | 7 | 0%none of 7 questions |
| PPG PPG Industries | 7 | 0%none of 7 questions |
| SHW The Sherwin-Williams Company | 7 | 0%none of 7 questions |
- APDAir Products · 11 questions18%2 of 11 questions
- CFCF Industries · 11 questions0%none of 11 questions
- DDDuPont · 11 questions0%none of 11 questions
- BALLBall Corporation · 8 questions0%none of 8 questions
- QQnity Electronics, Inc. · 8 questions0%none of 8 questions
- CTVACorteva · 7 questions0%none of 7 questions
- ECLEcolab · 7 questions0%none of 7 questions
- MOSMosaic Company (The) · 7 questions0%none of 7 questions
- PPGPPG Industries · 7 questions0%none of 7 questions
- SHWThe Sherwin-Williams Company · 7 questions0%none of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 1 | 0%none of 1 question | 1 |
| 2024 Q4 | 11 | 0%none of 11 questions | 9 |
| 2025 Q1 | 14 | 7%1 of 14 questions | 11 |
| 2025 Q2 | 12 | 0%none of 12 questions | 10 |
| 2025 Q3 | 16 | 0%none of 16 questions | 11 |
| 2025 Q4 | 15 | 0%none of 15 questions | 11 |
| 2026 Q1 | 13 | 8%1 of 13 questions | 9 |
| 2026 Q2 | 12 | 0%none of 12 questions | 10 |
- 2024 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2024 Q411 questions · challenge rate 0% (none of 11 questions) · 9 companies
- 2025 Q114 questions · challenge rate 7% (1 of 14 questions) · 11 companies
- 2025 Q212 questions · challenge rate 0% (none of 12 questions) · 10 companies
- 2025 Q316 questions · challenge rate 0% (none of 16 questions) · 11 companies
- 2025 Q415 questions · challenge rate 0% (none of 15 questions) · 11 companies
- 2026 Q113 questions · challenge rate 8% (1 of 13 questions) · 9 companies
- 2026 Q212 questions · challenge rate 0% (none of 12 questions) · 10 companies
Topics
Topics tagged on this analyst’s questions.
- Competitive Dynamics28
- Revenue Growth22
- Innovation & R&D20
- Demand20
- Capex Investment15
- Margin13
- Supply Chain11
- Cloud & AI9
- Pricing9
- Geographic Expansion9
Show all 19 topics
- Capital Allocation6
- Cost Pressure6
- Macroeconomic5
- Guidance Reliability4
- Product Launch3
- M&A3
- Regulation Policy2
- Trade Tariffs1
- Fx1